ADDvise Group successfully issues subsequent senior secured bonds of 250 MSEK
ADDvise Group AB (publ) ("ADDvise" or the "Company") announces today that the Company has successfully placed a subsequent senior secured bond issue (the “Subsequent Bond Issue) in an amount of 250 MSEK under the Company’s existing senior secured bond framework with ISIN SE0015222088. Following the Subsequent Bond Issue, the outstanding amount under the senior secured bonds will be 500 MSEK.
The transaction saw strong demand from both Nordic and international investors and was placed at 101.5% of par, corresponding to a yield of approximately 6.6%.
As previously communicated to the market via a press release on 29 October, the net proceeds from the Subsequent Bond Issue will be used to finance future acquisitions.
"Today’s tap issue of our bond framework above par demonstrates our ability to deliver on our targets. We will now speed up our M&A journey further", says Rikard Akhtarzand, CEO.
Pareto Securities AB acted as sole bookrunner and Roschier Advokatbyrå as legal advisor in connection with the bond issue.
For additional information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se
Important information:
This information is information that the ADDvise Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (596/2014/EU). The information was submitted for publication on 29 October 2021 at 16:45 CEST.
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.